ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Recruiting • Phase III • Rheumatology • NCT06617325.
- Dapirolizumab pegol added to standard treatment improves moderate to severe lupus disease activity.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. Conditions: Systemic Lupus Erythematosus Interventions: DZP, Placebo Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 450 participants